{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:02:00Z","timestamp":1782698520419,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.colsurfb.2021.111723","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:07:44Z","timestamp":1616803664000},"page":"111723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["PSMA conjugated combinatorial liposomal formulation encapsulating genistein and plumbagin to induce apoptosis in prostate cancer cells"],"prefix":"10.1016","volume":"203","author":[{"given":"Jing-yan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-liang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2021.111723_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188258","article-title":"Men\u2019s perspectives of prostate cancer screening: a systematic review of qualitative studies","volume":"12","author":"James","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0010","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0015","doi-asserted-by":"crossref","DOI":"10.2174\/1389200216666150625121546","article-title":"Nanotechnology in disease diagnostic techniques","author":"Savaliya","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0020","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1038\/s41598-018-20451-9","article-title":"Differential gene expression induced by anti-cancer agent plumbagin is mediated by androgen receptor in prostate cancer cells","volume":"8","author":"Rondeau","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9035452","article-title":"Plumbagin-loaded nanoemulsion drug delivery formulation and evaluation of antiproliferative effect on prostate Cancer cells","volume":"2018","author":"Chrastina","year":"2018","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0030","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.bmcl.2017.03.047","article-title":"Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB\/c mice","volume":"27","author":"Kang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10717544.2011.595840","article-title":"Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL\/6J mice bearing B16F1 melanoma","volume":"18","author":"Kumar","year":"2011","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0040","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/pros.23428","article-title":"Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: a pre-clinical study","volume":"77","author":"Abedinpour","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-319-41342-6_10","article-title":"Plumbagin and its role in chronic diseases","volume":"929","author":"Panichayupakaranant","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1142\/S0192415X17500264","article-title":"Anticancer properties and pharmaceutical applications of plumbagin: a review","volume":"45","author":"Liu","year":"2017","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0055","first-page":"349","article-title":"Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells","volume":"9","author":"Qiu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0060","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2147\/DDDT.S75976","article-title":"Induction of apoptosis and autophagy via sirtuin1- and PI3K\/Akt\/mTOR-mediated pathways by plumbagin in human prostate cancer cells","volume":"9","author":"Zhou","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1940-6207.CAPR-14-0231","article-title":"Plumbagin inhibits prostate carcinogenesis in intact and castrated PTEN knockout mice via targeting PKCepsilon, Stat3, and epithelial-to-Mesenchymal transition markers","volume":"8","author":"Hafeez","year":"2015","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0070","first-page":"77","article-title":"Transport of sugars in tumor cell membranes","volume":"355","author":"Hatanaka","year":"1974","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.metabol.2015.10.007","article-title":"Facilitative glucose transporters: implications for cancer detection, prognosis and treatment","volume":"65","author":"Barron","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0085","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/bjc.2017.323","article-title":"Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death","volume":"117","author":"Li","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0090","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.11293","article-title":"Expression and localization of GLUT1 and GLUT12 in prostate carcinoma","volume":"97","author":"Chandler","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jcb.23379","article-title":"Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue","volume":"113","author":"Reinicke","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0100","first-page":"1681","article-title":"Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells","volume":"73","author":"Zhang","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1535-7163.MCT-16-0285","article-title":"Nanoparticle-based celecoxib and plumbagin for the synergistic treatment of melanoma","volume":"16","author":"Gowda","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0120","first-page":"6357","article-title":"Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","article-title":"Prostate-specific membrane antigen expression as a predictor of prostate cancer progression","volume":"38","author":"Perner","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0090-4295(01)00983-9","article-title":"Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma","volume":"57","author":"Chang","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0135","first-page":"555","article-title":"Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises","volume":"28","author":"Santoni","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0140","first-page":"899","article-title":"Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix","volume":"30","author":"Barwe","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/pros.10199","article-title":"Dissociation between androgen responsiveness for malignant growth vs. Expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models","volume":"54","author":"Denmeade","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0150","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jso.2930590410","article-title":"Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men","volume":"59","author":"Douglas","year":"1995","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0155","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2174\/1381612822666151210123546","article-title":"Pharmacological drug delivery strategies for improved therapeutic effects: recent advances","volume":"22","author":"Savaliya","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0160","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1158\/0008-5472.CAN-12-1527","article-title":"Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns","volume":"72","author":"Singh","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJN.S124701","article-title":"Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells","volume":"13","author":"Singh","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/08982104.2016.1185731","article-title":"Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition","volume":"27","author":"Gao","year":"2017","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0175","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jconrel.2013.10.025","article-title":"Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft","volume":"172","author":"Shaikh","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.110966","article-title":"Improved drug delivery and anti-tumor efficacy of combinatorial liposomal formulation of genistein and plumbagin by targeting Glut1 and Akt3 proteins in mice bearing prostate tumor","volume":"190","author":"Song","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0185","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0190","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.01.041","article-title":"Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice","volume":"357","author":"Elbayoumi","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0195","doi-asserted-by":"crossref","first-page":"10170","DOI":"10.1021\/acsami.0c00331","article-title":"Serotonin-stearic acid bioconjugate-coated completely biodegradable Mn3O4 nanocuboids for hepatocellular carcinoma targeting","volume":"12","author":"Jain","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cis.2014.11.004","article-title":"Surface functionalization of quantum dots for biological applications","volume":"215","author":"Karakoti","year":"2015","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0205","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/pros.23868","article-title":"Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of (177) Lu-PSMA-617 in LNCaP cells","volume":"79","author":"Kranzbuhler","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0210","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Kranzbuhler","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/aja.2008.44","article-title":"The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer","volume":"11","author":"Yu","year":"2009","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0220","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.stem.2009.02.008","article-title":"A radical bailout strategy for cancer stem cells","volume":"4","author":"Tothova","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0225","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0230","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2017.474","article-title":"Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer","volume":"118","author":"Qu","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.01.002","article-title":"Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation","volume":"448","author":"Tian","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0240","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/jca.47532","article-title":"Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma","volume":"11","author":"Hu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.colsurfb.2021.111723_bib0245","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00589","article-title":"Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies","volume":"116","author":"Ulbrich","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12906-018-2155-3","article-title":"Plumbagin induces RPE cell cycle arrest and apoptosis via p38 MARK and PI3K\/AKT\/mTOR signaling pathways in PVR","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Complement. Altern. Med."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41419-017-0068-6","article-title":"Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0260","first-page":"537","article-title":"Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K\/Akt\/mTOR-mediated pathway in human pancreatic cancer cells","volume":"9","author":"Wang","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0265","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1289\/ehp.1103928","article-title":"Exposure to silver nanoparticles inhibits selenoprotein synthesis and the activity of thioredoxin reductase","volume":"120","author":"Srivastava","year":"2012","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.colsurfb.2021.111723_bib0270","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1021\/tx100040k","article-title":"Selective targeting of selenocysteine in thioredoxin reductase by the half mustard 2-chloroethyl ethyl sulfide in lung epithelial cells","volume":"23","author":"Jan","year":"2010","journal-title":"Chem. Res. Toxicol."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776521001673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776521001673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:57:54Z","timestamp":1760525874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776521001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":54,"alternative-id":["S0927776521001673"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2021.111723","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA conjugated combinatorial liposomal formulation encapsulating genistein and plumbagin to induce apoptosis in prostate cancer cells","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2021.111723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111723"}}